The goal of this clinical trial is to evaluate the efficacy and safety of oral paclitaxel plus fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in the neoadjuvant treatment of HER2+ breast cancer patients.
Absolute neutrophil count ≥ 1,500/mcL
Platelets ≥ 100,000/mcL
Hemoglobin ≥ 9.0 g/dL
Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
History of invasive breast cancer. Bilateral breast cancer or inflammatory breast cancer . Prior excisional and/or incisional biopsy of the primary tumor and/or axillary lymph nodes.
Unstable angina;
Clinically significant arrhythmias requiring medication;
Myocardial infarction within the past 6 months;
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead sponsor
Peking University Cancer Hospital & Institute
Collaborator
Peking University Shenzhen Hospital
Collaborator
Hainan People's Hospital
Collaborator
The Affiliated Hospital Of Guizhou Medical University
Collaborator
Nanfang Hospital, Southern Medical University
Collaborator
Guangdong Women and Children Hospital
Collaborator
Affiliated Cancer Hospital of Shantou University Medical College
Collaborator
First Affiliated Hospital of Wenzhou Medical University
Collaborator
Cancer Hospital of Guangxi Medical University
Collaborator